Orchard Therapeutics, which is developing gene therapies for rare diseases, filed on Thursday with the SEC to raise up to $173 million in an initial public offering.
The London, United Kingdom-based company was founded in 2015 and plans to list on the Nasdaq under the symbol ORTX. Orchard Therapeutics filed confidentially on August 6, 2018. J.P. Morgan, Goldman Sachs and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
